What insurance policy changes affect code E66.9?

There are 15 tracked policy changes affecting code E66.9, including updates from Aetna, Priority Health, Excellus BlueCross BlueShield. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code E66.9?

Payers that have issued tracked updates for code E66.9 include: Aetna, Priority Health, Excellus BlueCross BlueShield, Blue Cross of Idaho.

How do I get notified when code E66.9 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code E66.9. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code E66.9?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

PAYER POLICY CHANGES

E66.9 Insurance Policy Changes

ICD-10 E66.9 is officially defined as "Obesity, unspecified." code E66.9 is referenced in 15 tracked payer policy changes from Aetna, Priority Health, and 2 other payers. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code E66.9 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Aetna · Effective Dec 8, 2025High impact
Human Chorionic Gonadotropin (hCG) (CPB 1081, reviewed 12-2025-08)
Aetna updated its hCG (Human Chorionic Gonadotropin) clinical policy (CPB 1081) effective December 2025. Key coverage remains for ART/ovulation induction, cryptorchidism, hypogonadotropic hypogonadism, and acute GVHD, but the policy explicitly excludes coverage for hCG used solely for endometrium preparation in frozen embryo transfer (FET). Precertification is required for all hCG products (Novarel, Pregnyl, Ovidrel, generics), and specialty pharmacy medical necessity review may be bypassed if the underlying infertility procedure is pre-approved.
Priority Health · Identified Aug 13, 2026High impact
Reminder: Medicare Bridge PA requests aren't processed through Priority Health
Medicare GLP-1 weight loss prior authorization (PA) requests must be submitted through the Medicare GLP-1 Bridge Program, not directly to Priority Health. Prescribers must include obesity diagnosis codes (E66 family) and a Bridge referral note with prescriptions; the pharmacy initiates the eligibility check and PA process through the Bridge program, with determinations made within 72 hours.
Excellus BlueCross BlueShield · Effective May 21, 2026Medium impact
Bariatric and Metabolic Surgery 7.01.29
Excellus BlueCross BlueShield policy 7.01.29 has a current effective date of May 21, 2026. A code edit dated 06/16/26 added CPT 43889, transoral endoscopic sleeve gastroplasty (ESG), back to the policy after its erroneous removal, and the code is listed as (E/I) experimental/investigational with an effective date of 01/01/26. The policy covers surgical treatment of obesity by Roux-en-Y gastric bypass, biliopancreatic diversion with duodenal switch, SADI-S, laparoscopic adjustable gastric banding, and sleeve gastrectomy when all listed BMI, documentation and clearance criteria are met.
Aetna · Effective Aug 12, 2025Medium impact
Human Chorionic Gonadotropin (hCG) (CPB 1081, reviewed 2026-10-08)
Aetna considers chorionic gonadotropin products (Novarel, Pregnyl, Ovidrel and generic hCG) medically necessary for induction of oocyte maturation or release in assisted reproductive technology or ovulation induction, prepubertal cryptorchidism not due to anatomical obstruction, hypogonadotropic hypogonadism meeting listed criteria for inducing spermatogenesis, and steroid-refractory acute graft-versus-host disease under listed conditions. Use for endometrium preparation alone for frozen embryo transfer, idiopathic male infertility, idiopathic microphallus and obesity or weight loss is considered experimental, investigational or unproven.
Aetna · Identified Oct 7, 2026Medium impact
Brain Natriuretic Peptide Testing (CPB 0618, reviewed 2026-09-29)
Aetna considers measurement of plasma brain natriuretic peptide (BNP) medically necessary to differentiate dyspnea due to heart failure from pulmonary disease, to determine prognosis or severity in chronic heart failure, to screen for heart failure annually in adults with diabetes mellitus, to measure upon hospital admission and before discharge in acutely decompensated heart failure, for preoperative cardiac risk assessment before elevated-risk noncardiac surgery in members with known cardiovascular disease, age 65 or older, or age 45 or older with cardiovascular symptoms, and as an adjunct test for risk stratification of Stage C aortic stenosis. Serial BNP and NT-proBNP measurements and the other uses listed in the policy, such as diagnosing Kawasaki disease, are considered experimental, investigational, or unproven. CPT 83880 is covered when the selection criteria are met, except as a cardiovascular biomarker in healthy normal subjects and for identifying stress-induced myocardial ischemia.
Aetna · Identified Oct 5, 2026Medium impact
Total Ankle Arthroplasty (CPB 0645, reviewed 2026-09-14)
Aetna's Clinical Policy Bulletin 0645 covers total ankle arthroplasty with an FDA-cleared implant for severe ankle arthritis when a set of criteria is met, including at least 6 months of documented conservative care with in-person physical therapy, and covers revision for a failed prosthesis. It treats custom implants, trans-fibular replacement, total talar replacement and intraoperative infection frozen-section analysis as experimental. The source shows a review date of 2026-09-14 but states no effective date, and this is an older source first detected by PolicyChanges on 2026-10-05, so treat it as historical material.
Aetna · Identified Aug 19, 2026Medium impact
Weight Reduction Programs and Devices (CPB 0039, reviewed 2026-03-10)
Aetna considers clinician-supervised weight reduction counseling for adults with a BMI of 30 or greater medically necessary up to a combined limit of 26 individual or group visits by any recognized provider per 12-month period. The FDA-cleared Plenity device is considered medically necessary to aid weight management in overweight and obese adults with a BMI of 25 to 40 kg/m2 when used with diet and exercise. For very low calorie diets (less than 799 kcal/day) in obese members, the listed EKG, lipid profile and chemistry tests are covered for up to 16 weeks, while exercise programs, special diet supplements, hospital confinement for a weight reduction program, and many experimental interventions such as wearable devices and sodium-glucose co-transporter 2 inhibitors are not covered or are considered experimental, investigational, or unproven for weight reduction.
Aetna · Identified Aug 18, 2026Medium impact
Nutritional Counseling (CPB 0049, reviewed 2026-03-10)
Aetna considers nutritional counseling a medically necessary preventive service for children and adults who are obese, and for adults who are overweight and have hypertension, dyslipidemia, impaired fasting glucose, or metabolic syndrome, when a provider recognized under the plan furnishes it. Aetna also considers counseling medically necessary for other chronic conditions where dietary adjustment has a therapeutic role, including diabetes, eating disorders, gastrointestinal disorders, hypertension, kidney disease, and seizures (ketogenic diet). Aetna considers counseling of unproven value for asthma, attention-deficit hyperactivity disorder, and chronic fatigue syndrome, and considers the NutrEval test experimental, investigational, or unproven.
Aetna · Identified Aug 17, 2026Medium impact
Hippotherapy (CPB 0151, reviewed 2026-03-20)
Aetna considers hippotherapy, also called equine therapy, experimental, investigational, or unproven for the listed indications and for all other indications, because its effectiveness has not been established. The listed indications include autism, attention deficit and/or hyperactivity disorder, cerebral palsy or other motor dysfunctions, chronic pain, dementia, developmental delays, Down's syndrome, epilepsy, idiopathic scoliosis, post-traumatic stress disorder, childhood obesity, and substance use disorder. HCPCS code S8940 (equestrian/hippotherapy, per session) and the listed ICD-10 codes are not covered for these indications.
Aetna · Identified Aug 17, 2026Medium impact
Helicobacter Pylori Infection Testing (CPB 0177, reviewed 2026-03-20)
Aetna considers FDA-cleared carbon isotope (13C or 14C) urea breath testing and stool antigen testing (HpSA) medically necessary for active Helicobacter pylori infection in selected persons, including adults with idiopathic thrombocytopenic purpura, persons before bariatric surgery, persons before starting proton pump inhibitor therapy for dyspepsia, and persons taking long term, low-dose aspirin or initiating chronic NSAID treatment. Nucleic acid amplification for clarithromycin resistance testing is medically necessary for selecting salvage regimens for treatment-experienced individuals with persistent H. pylori infection. H. pylori serology, the AmHPR panel, IL-1B and TNFA gene polymorphism testing, and urea breath or stool antigen testing for other indications such as stroke risk, dementia risk and screening of asymptomatic persons are considered experimental, investigational or unproven.
Aetna · Identified Aug 15, 2026Medium impact
Fecal Bacteriotherapy (CPB 0844, reviewed 2026-03-25)
Aetna's commercial clinical policy bulletin 0844 covers fecal bacteriotherapy. It considers fecal microbiota transplant medically necessary for Clostridium difficile infection (CDI) confirmed by a positive C. difficile toxin stool test that has recurred after at least one course of adequate antibiotic therapy. It considers a single rectal dose of Rebyota (fecal microbiota, live-jslm) medically necessary for preventing CDI when the policy's criteria are met, and it considers other listed indications, including alcoholic hepatitis, Crohn's disease, ulcerative colitis and irritable bowel syndrome, experimental, investigational, or unproven.
Aetna · Identified Aug 14, 2026Medium impact
Embolization: Selected Procedures (CPB 0856, reviewed 2026-01-12)
Aetna considers alcohol embolization or sclerotherapy and/or surgery for symptomatic venous malformations medically necessary when there is pain, swelling, ulceration, or hemorrhage. Coil embolization is medically necessary for arterio-venous malformations and aneurysms, congenital aorto-azygous fistula, splenic artery aneurysm and gastric varices, and embolization is medically necessary for lower gastro-intestinal bleeding, for renal angiomyolipoma with active bleeding or a size greater than 6 cm, and for several other listed indications. Aetna considers hemorrhoidal embolization, endovascular lymphatic ablation, Onyx embolization for the treatment of CSF vertebral vein fistula, coil embolization of the hypogastric veins for deep vein thrombosis, and several other listed procedures experimental, investigational, or unproven.
Aetna · Identified Aug 13, 2026Medium impact
Pediatric Intensive Feeding Programs (CPB 0809, reviewed 2025-12-11)
Aetna considers professional services for pediatric intensive feeding programs medically necessary for infants and children with complex feeding and swallowing disorders when an interdisciplinary team provides the care and every listed condition is met. Those conditions include behavior problems interfering with feeding, a documented diagnosis-specific treatment plan with estimated length of treatment, medical causes of failure to thrive treated without resolving the feeding problem, physician coordination and oversight, one of the listed feeding problems, and no response to initial treatment by a single discipline over a 2-month period. Other indications, such as childhood obesity and Prader-Willi syndrome, are considered experimental, investigational, or unproven, and electrical stimulation for swallowing or feeding disorders is also considered experimental, investigational, or unproven.
Aetna · Identified Aug 12, 2026Medium impact
Vitamin D Assay (CPB 0945, reviewed 2025-12-23)
Aetna considers measurements of serum 25-hydroxyvitamin D experimental, investigational, or unproven for routine preventive screening. CPT codes 0038U, 82306 and 82652 are covered if selection criteria are met, and ICD-10 codes covered if selection criteria are met include vitamin D deficiency (E55.0 to E55.9), chronic kidney disease (N18.1 to N18.9) and osteoporosis (M80.00xA to M81.8). ICD-10 codes not covered for the indications listed in the policy include malignant neoplasms of the breast (C50.011 to C50.929) and prostate (C61), diabetes mellitus (E08.00 to E13.9), Alzheimer's disease (G30.0 to G30.9) and screening encounters for malignant neoplasms (Z12.0 to Z12.9).
Blue Cross of Idaho · Identified Jun 19, 2026Medium impact
One-to-One for HealthCare - Fall Edition
Medical policy 7.01.645 for laminectomy added AIM guideline criteria and policy statements for CPT codes 63048, 63196, 63198, 63200, 63250, 63252, 63265 and 63267, effective October 1, 2021. Provider documentation for obesity and protein-calorie malnutrition should include the diagnosis, status and plan (DSP) of any condition taken into consideration during medical decision-making. The diagnosis coding guidance for obesity, protein-calorie malnutrition and BMI lists the ICD-10-CM codes that apply and requires provider documentation to justify reporting BMI codes.

Watch E66.9

Get one email when a payer policy names E66.9, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Human Chorionic Gonadotropin (hCG) (CPB 1081, reviewed 12-2025-08)

Reminder: Medicare Bridge PA requests aren't processed through Priority Health

Bariatric and Metabolic Surgery 7.01.29

Human Chorionic Gonadotropin (hCG) (CPB 1081, reviewed 2026-10-08)

Brain Natriuretic Peptide Testing (CPB 0618, reviewed 2026-09-29)

Total Ankle Arthroplasty (CPB 0645, reviewed 2026-09-14)

Weight Reduction Programs and Devices (CPB 0039, reviewed 2026-03-10)

Nutritional Counseling (CPB 0049, reviewed 2026-03-10)

Hippotherapy (CPB 0151, reviewed 2026-03-20)

Helicobacter Pylori Infection Testing (CPB 0177, reviewed 2026-03-20)

Fecal Bacteriotherapy (CPB 0844, reviewed 2026-03-25)

Embolization: Selected Procedures (CPB 0856, reviewed 2026-01-12)

Pediatric Intensive Feeding Programs (CPB 0809, reviewed 2025-12-11)

Vitamin D Assay (CPB 0945, reviewed 2025-12-23)

One-to-One for HealthCare - Fall Edition

What insurance policy changes affect code E66.9?

Which payers have updated policy for code E66.9?

How do I get notified when code E66.9 policy changes?

Why do payers change policies for code E66.9?